Skip to main content

Rare Disease Drug Market to Witness Huge Growth by 2026 : Novartis, Celgene, Pfizer, Sanofi

Edison, NJ -- (SBWIRE) -- 12/03/2020 -- Rare Disease Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version) is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Rare Disease Drug Market. Some of the key players profiled in the study are Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline, Merck & Co., Inc., Johnson & Johnson, Biogen, Inc., Shire, Amgen, Inc., Deciphera, Atara Biotherapeutics & ProQR.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.